Evidence map›Paper›PMID 36112575›Full record

ArticlePloS one2022

Self-assembling protein nanoparticles and virus like particles correctly display β-barrel from meningococcal factor H-binding protein through genetic fusion.

Luigia Cappelli, Paolo Cinelli, Fabiola Giusti, Ilaria Ferlenghi, Sabrina Utrio-Lanfaloni, Newton Wahome, Matthew James Bottomley, Domenico Maione, Roberta Cozzi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Engineering Microbial Particles for Next-Generation Biomedical Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Improving the immunogenicity ofFrontiers in immunology · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. A perspective on SARS-CoV-2 virus-like particles vaccines.International immunopharmacology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Luigia CappelliUniversity of Bologna, Bologna, Italy.ORCID 0000-0002-3991-3611
Paolo CinelliUniversity of Bologna, Bologna, Italy.
Fabiola GiustiGSK, Siena, Italy.
Ilaria FerlenghiGSK, Siena, Italy.
Sabrina Utrio-LanfaloniGSK, Siena, Italy.
Newton WahomeGSK, Rockville, Maryland, United States of America.
Matthew James BottomleyGSK, Siena, Italy.ORCID 0000-0001-9734-5694
Domenico MaioneGSK, Siena, Italy.
Roberta CozziGSK, Siena, Italy.ORCID 0000-0001-7774-6167
University of Bologna · ITGlaxoSmithKline (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant protein-based vaccines are a valid and safer alternative to traditional vaccines based on live-attenuated or killed pathogens. However, the immune response of subunit vaccines is generally lower compared to that elicited by traditional vaccines and usually requires the use of adjuvants. The use of self-assembling protein nanoparticles, as a platform for vaccine antigen presentation, is emerging as a promising approach to enhance the production of protective and functional antibodies. In this work we demonstrated the successful repetitive antigen display of the C-terminal β-barrel domain of factor H binding protein, derived from serogroup B Meningococcus on the surface of different self-assembling nanoparticles using genetic fusion. Six nanoparticle scaffolds were tested, including virus-like particles with different sizes, geometries, and physicochemical properties. Combining computational and structure-based rational design we were able generate antigen-fused scaffolds that closely aligned with three-dimensional structure predictions. The chimeric nanoparticles were produced as recombinant proteins in Escherichia coli and evaluated for solubility, stability, self-assembly, and antigen accessibility using a variety of biophysical methods. Several scaffolds were identified as being suitable for genetic fusion with the β-barrel from fHbp, including ferritin, a de novo designed aldolase from Thermotoga maritima, encapsulin, CP3 phage coat protein, and the Hepatitis B core antigen. In conclusion, a systematic screening of self-assembling nanoparticles has been applied for the repetitive surface display of a vaccine antigen. This work demonstrates the capacity of rational structure-based design to develop new chimeric nanoparticles and describes a strategy that can be utilized to discover new nanoparticle-based approaches in the search for vaccines against bacterial pathogens.

Indexed as

Meningococcal VaccinesNanoparticlesNeisseria meningitidisAldehyde-LyasesAntigensBacterial VaccinesCarrier ProteinsComplement Factor HFerritinsHepatitis B Core AntigensRecombinant ProteinsVaccines, CombinedVaccines, SubunitAldehyde-LyasesAntigensBacterial VaccinesCarrier ProteinsComplement Factor HFerritinsHepatitis B Core AntigensMeningococcal VaccinesRecombinant ProteinsVaccines, CombinedVaccines, Subunit

Identifiers

PMID36112575
PMCPMC9480994
OpenAlexW4296033646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.